In the European Union and the United States,<unk>  is indicated for the extended adjuvant treatment of adults with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. In the United States, it is also indicated, in combination with capecitabine, for the treatment of adults with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
Neratinib
Tucatinib
Fostamatinib
Dasatinib
Lapatinib
Ponatinib
Capmatinib
Pemigatinib